Development and Characterization of Selective FAK Inhibitors and PROTACs with <i>In Vivo</i> Activity
Eriko Koide(Dana-Farber Cancer Institute), Behnam Nabet(University of Washington)
Cited by 16
Related Papers
Development of PROTACs for targeted degradation of oncogenic TRK fusions
|bioRxiv (Cold Spring Harbor Laboratory)|2025|0
Development of PROTACs for targeted degradation of oncogenic TRK fusions
|RSC Chemical Biology|2026|0